Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

plasmid DNA vaccine pING-hHER3FL

A plasmid DNA cancer vaccine encoding the tumor-associated antigen (TAA) human epidermal growth factor receptor type-3 (HER-3; HER3), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration of the plasmid DNA vaccine pING-hHER3FL and after cellular uptake by muscle cells, the plasmid DNA expresses HER-3 which, may elicit both antigen-specific cytotoxic T-lymphocyte (CTL) and humoral immune responses against tumor cells expressing HER-3. HER-3 plays a key role in tumor cell proliferation and its overexpression is associated with poor prognosis. HER-3 is associated with tumor cell resistance to anti-HER-2 therapeutics.
Synonym:pING-hHER3FL vaccine
Code name:pING-hHER3FL
Search NCI's Drug Dictionary